Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. Dezember 2015 07:00 ET | Quelle: Cara Therapeutics

Cara Therapeutics Announces Positive Top-Line Results From Phase 2a Trial of Oral CR845 in Chronic Pain Patients With Osteoarthritis of the Knee or Hip

Dose-related reduction observed in mean baseline pain score up to 34 percent after two weeks, with statistically significant reduction in mean rescue medication for top 5.0 mg dose All four...
01. Dezember 2015 08:00 ET | Quelle: Cara Therapeutics

Cara Therapeutics to Present Poster at the ASHP 2015 Midyear Clinical Meeting

SHELTON, Conn., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
25. November 2015 08:00 ET | Quelle: Cara Therapeutics

Cara Therapeutics to Webcast Presentation at the Piper Jaffray 27th Annual Healthcare Conference

SHELTON, Conn., Nov. 25, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
11. November 2015 08:00 ET | Quelle: Cara Therapeutics

Cara Therapeutics to Webcast Presentation at the Stifel 2015 Healthcare Conference

SHELTON, Conn., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
09. November 2015 16:01 ET | Quelle: Cara Therapeutics

Cara Therapeutics Reports Third Quarter 2015 Financial Results

– Initiated Phase 3 program for I.V. CR845 in acute postoperative pain – – Initiated Phase 2a trial of Oral CR845 in osteoarthritis patients – – Earned $2.75M in...
02. November 2015 16:30 ET | Quelle: Cara Therapeutics

Cara Therapeutics to Announce Third Quarter 2015 Financial Results on November 9, 2015

SHELTON, Conn., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
29. Oktober 2015 08:00 ET | Quelle: Cara Therapeutics

Cara Therapeutics to Present Late-Breaking Poster at Kidney Week 2015

SHELTON, Conn., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
26. Oktober 2015 08:00 ET | Quelle: Cara Therapeutics

Cara Therapeutics to Present at 2nd Human Abuse Liability & Abuse-Deterrent Formulations Conference

Chief Medical Officer Dr. Joseph Stauffer to discuss potential for kappa opioids SHELTON, Conn., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology...
19. Oktober 2015 08:00 ET | Quelle: Cara Therapeutics

Cara Therapeutics to Sponsor Symposium and Present Poster at ANESTHESIOLOGY 2015

Pain experts to discuss trends in kappa opioid receptor agonists and the future of postoperative pain management Company to present positive data from Phase 2 acute pain trials of I.V....
13. Oktober 2015 08:00 ET | Quelle: Cara Therapeutics

Cara Therapeutics Achieves Milestone Payments From Japan and South Korea Partners for Development of CR845 in Uremic Pruritus

$2.5M Milestones Earned for Advancement of CR845 in Phase 2 Clinical Trials in U.S. and Japan SHELTON, Conn., Oct. 13, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a...

Nächste Seite